Improved Outcomes with Advancements in High Intensity Focused Ultrasound Devices for the Treatment of Localized Prostate Cancer
We evaluated the association between long-term clinical outcomes and morbidity with high intensity focused ultrasound.
Materials and Methods:
We included patients with stage T1c-T3N0M0 prostate cancer who were treated with Sonablate® (SB) devices during 1999 to 2012 and followed for more than 2 years. Risk stratification and complication rates were compared among the treatment groups (ie SB200/500 group, SB500 version 4 group and SB500 tissue change monitor group). Primary study outcomes included overall, cancer specific and biochemical disease-free survival rates determined using Kaplan-Meier analysis (Phoenix definition). Secondary outcomes included predictors of biochemical disease-free survival using Cox models.
A total of 918 patients were included in the study. Median followup in the SB200/500, SB500 version 4 and the SB500 tissue change monitor groups was 108, 83 and 47 months, respectively. The 10-year overall and cancer specific survival rates were 89.6% and 97.4%, respectively. The 5-year biochemical disease-free survival rate in the SB200/500, SB500 version 4 and SB500 tissue change monitor group was 48.3%, 62.3% and 82.0%, respectively (p <0.0001). The overall negative biopsy rate was 87.3%. On multivariate analysis pretreatment prostate specific antigen, Gleason score, stage, neoadjuvant androgen deprivation therapy and high intensity focused ultrasound devices were significant predictors of biochemical disease-free survival. Urethral stricture, epididymitis, urinary incontinence and rectourethral fistula were observed in 19.7%, 6.2%, 2.3% and 0.1% of cases, respectively.
Long-term followup of patients with high intensity focused ultrasound demonstrated improved clinical outcomes due to technical, imaging and technological advancements.
- 1 American Cancer Society: Cancer Facts & Figures 2014. Available at www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/. Accessed March 8, 2014. Google Scholar
- 2 : EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol2014; 65: 124. Google Scholar
- 3 : Cancer progression and survival rate following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol2004; 172: 910. Link, Google Scholar
- 4 : Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med2014; 370: 932. Google Scholar
- 5 : Outcome and toxicity for patients treated with intensity modulated radiation therapy for localized prostate cancer. J Urol2013; 190: 521. Link, Google Scholar
- 6 : Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys2013; 85: 686. Google Scholar
- 7 : Multi-institutional analysis of long-term outcome for stage T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys2007; 67: 327. Google Scholar
- 8 : Ten-year biochemical disease control for patients with prostate cancer treated with cryosurgery as primary therapy. Urology2008; 71: 515. Google Scholar
- 9 : Laparoscopic radical prostatectomy for localized prostate cancer: a systematic review of comparative studies. J Urol2006; 175: 2011. Link, Google Scholar
- 10 : Oncological outcomes after robot-assisted radical prostatectomy: long term follow-up in 4,803 patients. BJU Int2013; . Epub ahead of print. Google Scholar
- 11 : Treatment of prostate cancer with transrectal focused ultrasound: early clinical experience. Eur Urol1996; 29: 174. Google Scholar
- 12 : Transrectal high-intensity focused ultrasound for the treatment of localized prostate cancer: eight-year experience. Int J Urol2009; 16: 881. Google Scholar
- 13 : High-intensity focused ultrasound therapy for prostate cancer. Int J Urol2012; 19: 187. Google Scholar
- 14 : Fourteen-year oncological and functional outcomes of high-intensity focused ultrasound in localized prostate cancer. BJU Int2013; 112: 322. Google Scholar
- 15 : Evolution and outcomes of 3 MHz high intensity focused ultrasound therapy for localized prostate cancer during 15 years. J Urol2013; 190: 702. Link, Google Scholar
- 16 : Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients. Eur Urol2014; 65: 907. Google Scholar
- 17 : Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys2006; 65: 965. Google Scholar
- 18 : Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg2004; 240: 205. Google Scholar
- 19 : The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. Int J Impot Res2002; 14: 245. Google Scholar
- 20 : Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA1998; 280: 969. Crossref, Medline, Google Scholar
- 21 : Transurethral resection of the prostate immediately after high-intensity focused ultrasound treatment for prostate cancer. Int J Urol2010; 17: 924. Google Scholar
- 22 : Will focal therapy become a standard of care for men with localized prostate cancer?. Nat Clin Pract Oncol2007; 4: 632. Google Scholar
- 23 : Morbidity of focal therapy in the treatment of localized prostate cancer. Eur Urol2013; 63: 618. Google Scholar